Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.66 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.54 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.54 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.54 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4318196 | 0.91 | CSF1R (0.66) | CSF1RKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL13340328 | 0.85 | CSF1R (0.65) | CSF1RAURKADDR1KCNK3MEN1 | |
| SCHEMBL13340335 | 0.81 | CSF1R (0.65) | CSF1RDDR1 | |
| SCHEMBL3475948 | 0.79 | CSF1R (1.00) | CSF1RKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL3475951 | 0.79 | CSF1R (1.00) | CSF1RKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL13340366 | 0.79 | CSF1R (1.00) | CSF1RKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4323640 | 0.76 | CSF1R (0.66) | CSF1RDDR1KCNK3MEN1KMT2A | |
| SCHEMBL13340342 | 0.75 | CSF1R (0.76) | CSF1RKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4312554 | 0.75 | BRAF (0.51) | CSF1RAURKADDR2DDR1MAPT | |
| SCHEMBL17052860 | 0.74 | MAPT (0.70) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029386-B2 | Pyridine derivatives useful as kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CSF1R 62/4885KCNQ3 3485/4885KCNQ2 4175/4885 |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CSF1R 62/4885KCNQ3 3485/4885KCNQ2 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.